LTR Pharma (ASX:LTP) said over 1,000 prescriptions of Spontan had been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme, according to a Wednesday Australian bourse filing.
Under the scheme, clinicians can request access to Spontan where approved treatments are unsuitable, ineffective, or unavailable.
De-identified data collection from the prescriptions under the scheme is ongoing.
Its shares rose 2% in recent trading on Wednesday.